PMID- 22761669
OWN - NLM
STAT- MEDLINE
DCOM- 20130326
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 6
DP  - 2012
TI  - Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small 
      cell lung cancer (NSCLC) patients.
PG  - e38150
LID - 10.1371/journal.pone.0038150 [doi]
LID - e38150
AB  - AIM: To determine the pharmacogenetics of platinum-based chemotherapy in Non 
      Small Cell Lung Cancer (NSCLC) patients. METHODS: Publications were selected from 
      PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted 
      to determine the association between genetic polymorphisms and platinum-based 
      chemotherapy by checking odds ratio (OR) and 95% confidence interval (CI). 
      RESULTS: Data were extracted from 24 publications, which included 11 
      polymorphisms in 8 genes for meta-analysis. MDR1 C3435T (OR = 1.97, 95% CI: 
      1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and 
      GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly 
      correlated with platinum-based chemotherapy in Asian NSCLC patients. CONCLUSION: 
      Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for 
      personalized chemotherapy treatment for NSCLC patients in Asian population in the 
      future.
FAU - Yin, Ji-Ye
AU  - Yin JY
AD  - Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, 
      Central South University, Changsha, China.
FAU - Huang, Qiong
AU  - Huang Q
FAU - Zhao, Ying-Chun
AU  - Zhao YC
FAU - Zhou, Hong-Hao
AU  - Zhou HH
FAU - Liu, Zhao-Qian
AU  - Liu ZQ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20120626
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers, Tumor)
RN  - 49DFR088MY (Platinum)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - *Pharmacogenetics
MH  - Platinum/*therapeutic use
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Prognosis
PMC - PMC3383686
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2012/07/05 06:00
MHDA- 2013/03/27 06:00
PMCR- 2012/06/26
CRDT- 2012/07/05 06:00
PHST- 2012/02/15 00:00 [received]
PHST- 2012/05/01 00:00 [accepted]
PHST- 2012/07/05 06:00 [entrez]
PHST- 2012/07/05 06:00 [pubmed]
PHST- 2013/03/27 06:00 [medline]
PHST- 2012/06/26 00:00 [pmc-release]
AID - PONE-D-12-04527 [pii]
AID - 10.1371/journal.pone.0038150 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(6):e38150. doi: 10.1371/journal.pone.0038150. Epub 2012 Jun 26.